Antibody-drug conjugate

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Tuesday, July 27, 2021 - 8:00am

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Tuesday, July 27, 2021 - 8:00am

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Tuesday, July 27, 2021 - 8:00am

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • This agreement with Byondis highlights the potential of our GlycoTarget discovery and technology platform, said Henner Kollenberg, Managing Director of Glycotope.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO

Wednesday, July 21, 2021 - 1:30pm

Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").

Key Points: 
  • Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").
  • Since the initial announcement of Dr. Krantz' planned appointment on December 17, 2020, he has been working diligently in preparation for this transition.
  • Dr. Benjamin Krantz, Director and CEO stated, "I am extremely excited to be taking on the role of CEO at APTI.
  • Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads.

Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

Thursday, July 22, 2021 - 1:00pm

The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect glycan conjugation and HydraSpace polar spacer technologies, both of which are known to optimize the therapeutic properties (efficacy and safety) of ADCs.

Key Points: 
  • The deal provides access to multiple novel linker-payload technologies developed by Synaffix and includes access to the GlycoConnect glycan conjugation and HydraSpace polar spacer technologies, both of which are known to optimize the therapeutic properties (efficacy and safety) of ADCs.
  • Under the terms of the agreement, Synaffix is eligible to receive upfront and potential milestone payments worth up to $246 million, plus tiered royalties on net sales.
  • Through our collaboration with Synaffix, we can access multiple potent ADC linker-payloads and efficiently optimize the competitive position of our therapeutic pipeline.
  • The ProfoundBio team brings multiple decades of valuable ADC development experience from Seattle Genetics (now Seagen) and MSD.

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

Thursday, July 15, 2021 - 9:01pm

ET on Friday, July 30, 2021 to discuss its second quarter operating results.

Key Points: 
  • ET on Friday, July 30, 2021 to discuss its second quarter operating results.
  • To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134.
  • The call may also be accessed through the Investors and Media section of the Companys website, www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

Adcendo Appoints Michael Pehl as Chief Executive Officer

Wednesday, July 7, 2021 - 8:30am

COPENHAGEN, Denmark, July 7, 2021 /PRNewswire/ -- Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer (CEO).

Key Points: 
  • COPENHAGEN, Denmark, July 7, 2021 /PRNewswire/ -- Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer (CEO).
  • Henrik Stage, co-founder of Adcendo, will move to the role of Chief Financial Officer.
  • John Haurum, Chairman of the Board of Adcendo, said: "We are delighted to welcome Michael to Adcendo.
  • Michael Pehl, Chief Executive Officer of Adcendo, added: "I am incredibly excited to join Adcendo and help advancing our ADCs into the next wave of development.

Adcendo Appoints Michael Pehl as Chief Executive Officer

Wednesday, July 7, 2021 - 8:30am

- Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record

Key Points: 
  • - Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record
    COPENHAGEN, Denmark, July 7, 2021 /PRNewswire/ -- Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer (CEO).
  • Henrik Stage, co-founder of Adcendo, will move to the role of Chief Financial Officer.
  • John Haurum, Chairman of the Board of Adcendo, said: "We are delighted to welcome Michael to Adcendo.
  • Michael Pehl, Chief Executive Officer of Adcendo, added: "I am incredibly excited to join Adcendo and help advancing our ADCs into the next wave of development.

Debiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® Conjugates

Wednesday, June 16, 2021 - 1:34pm

The two companies are aiming to develop a new drug modality known as Antibody DegraducerConjugates (ADeC), by combining one of Ubix's Degraducer molecule, with Debiopharm's antibody drug conjugate linker Multilink.

Key Points: 
  • The two companies are aiming to develop a new drug modality known as Antibody DegraducerConjugates (ADeC), by combining one of Ubix's Degraducer molecule, with Debiopharm's antibody drug conjugate linker Multilink.
  • Multilink is a new cleavable linker platform that allows the loading of multiple drug payloads on an antibody.
  • Combining these advanced biotechnology solutions offers the unique opportunity to produce new types of antibody conjugates with dual molecular targeting.
  • These antibody Degraducerconjugates could extend the range of therapeutic antibody conjugates available for the treatment of various cancers.

ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

Wednesday, June 9, 2021 - 12:15pm

Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.

Key Points: 
  • Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload.
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.